Targeting IL-17A to combat immune-related adverse events

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-08-29 DOI:10.1038/s43018-024-00804-2

Kailan Sierra-Davidson, Genevieve M. Boland

引用次数: 0

Abstract

The clinical utility of immune checkpoint inhibitors is limited by immune-related adverse events (irAEs); understanding the mechanisms of irAE development is thus crucial. A study reports that IL-17A-expressing CD4+ T cells were elevated at irAE onset and provides proof of concept for using IL-17A blockade to improve irAEs in two patients.

Abstract Image

查看原文本刊更多论文

以 IL-17A 为靶点，应对免疫相关不良事件。

免疫检查点抑制剂的临床应用受到免疫相关不良事件（irAEs）的限制；因此，了解irAE的发生机制至关重要。一项研究报告称，IL-17A表达的CD4+ T细胞在irAE发生时升高，并提供了使用IL-17A阻断改善两名患者irAEs的概念证明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.